Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 69.96
BTX's Cash to Debt is ranked higher than
73% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. BTX: 69.96 )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 69.96

Equity to Asset 0.20
BTX's Equity to Asset is ranked higher than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BTX: 0.20 )
BTX' s 10-Year Equity to Asset Range
Min: -45.87   Max: 0.99
Current: 0.2

-45.87
0.99
Interest Coverage No Debt
BTX's Interest Coverage is ranked higher than
68% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BTX: No Debt )
BTX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -4.34
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1248.45
BTX's Operating margin (%) is ranked higher than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. BTX: -1248.45 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46   Max: -116.83
Current: -1248.45

-9788.46
-116.83
Net-margin (%) -865.49
BTX's Net-margin (%) is ranked higher than
57% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. BTX: -865.49 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15   Max: -137.48
Current: -865.49

-9471.15
-137.48
ROE (%) -299.82
BTX's ROE (%) is ranked higher than
51% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. BTX: -299.82 )
BTX' s 10-Year ROE (%) Range
Min: -2802.7   Max: -49.44
Current: -299.82

-2802.7
-49.44
ROA (%) -84.83
BTX's ROA (%) is ranked higher than
56% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. BTX: -84.83 )
BTX' s 10-Year ROA (%) Range
Min: -624.96   Max: -33.33
Current: -84.83

-624.96
-33.33
ROC (Joel Greenblatt) (%) -2247.02
BTX's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. BTX: -2247.02 )
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21242.11   Max: -800
Current: -2247.02

-21242.11
-800
Revenue Growth (%) -3.90
BTX's Revenue Growth (%) is ranked higher than
74% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. BTX: -3.90 )
BTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 128.9
Current: -3.9

0
128.9
EBITDA Growth (%) 63.40
BTX's EBITDA Growth (%) is ranked higher than
98% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. BTX: 63.40 )
BTX' s 10-Year EBITDA Growth (%) Range
Min: -48.9   Max: 63.9
Current: 63.4

-48.9
63.9
EPS Growth (%) 42.50
BTX's EPS Growth (%) is ranked higher than
95% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BTX: 42.50 )
BTX' s 10-Year EPS Growth (%) Range
Min: -35.6   Max: 67.1
Current: 42.5

-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

Q1 2014

BTX Guru Trades in Q1 2014

Jim Simons 51,700 sh (New)
» More
Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 33.00
BTX's P/B is ranked higher than
58% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. BTX: 33.00 )
BTX' s 10-Year P/B Range
Min: 5.65   Max: 83
Current: 33

5.65
83
P/S 36.67
BTX's P/S is ranked higher than
72% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. BTX: 36.67 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 124
Current: 36.67

4.83
124
EV-to-EBIT -4.55
BTX's EV-to-EBIT is ranked higher than
50% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BTX: -4.55 )
BTX' s 10-Year EV-to-EBIT Range
Min: -71.6   Max: -1.1
Current: -4.55

-71.6
-1.1
Current Ratio 1.72
BTX's Current Ratio is ranked higher than
57% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. BTX: 1.72 )
BTX' s 10-Year Current Ratio Range
Min: 0.02   Max: 76
Current: 1.72

0.02
76
Quick Ratio 1.67
BTX's Quick Ratio is ranked higher than
59% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. BTX: 1.67 )
BTX' s 10-Year Quick Ratio Range
Min: 0.02   Max: 74
Current: 1.67

0.02
74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.02
BTX's Price/Median PS Value is ranked higher than
85% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. BTX: 1.02 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 15.74
Current: 1.02

0.14
15.74
Earnings Yield (Greenblatt) -22.00
BTX's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BTX: -22.00 )
BTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -22

Forward Rate of Return (Yacktman) 66.06
BTX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. BTX: 66.06 )
BTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -159   Max: 5235.2
Current: 66.06

-159
5235.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at... Nov 19 2014
BIOTIME INC Financials Nov 15 2014
BIOTIME INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
BioTime Reports Third Quarter Results and Recent Progress Nov 10 2014
BIOTIME INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014
BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa... Nov 03 2014
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 03 2014
BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa... Nov 03 2014
Asterias Biotherapeutics to Report Third Quarter Results on November 10, 2014 Oct 31 2014
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement Oct 22 2014
Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of... Oct 20 2014
Bloomberg Advantage: ING’s Brzeski, BioTime CEO, Mayor Warren Oct 10 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Oct 09 2014
BioTime, Inc. Closes $31 Million Financing Oct 09 2014
Asterias Biotherapeutics to List its Series A Common Stock on NYSE MKT Oct 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK